Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 152,785 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Condition Clear all
Completed Not applicable Interventional Results available

Proteolytic Enzyme Induction Within the Human Myocardial Interstitium

NCT00744211
View directory record Official record
Conditions
Heart Disease
Interventions
1mg/kg sitaxsentan sodium, 2mg/kg sitaxsentan sodium, Vehicle
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

Multi Immunotherapy to Test Tolerance and Xolair

NCT02626611
View directory record Official record
Conditions
Food Allergy
Interventions
Omalizumab, Food Flour Buildup
Drug
Lead sponsor
Kari Christine Nadeau
Other
Eligibility
4 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Mountain View, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Phase 1 Interventional

A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT01711671
View directory record Official record
Conditions
Multiple Myeloma
Interventions
DKN-01 300 mg, DKN-01 600 mg, Standard of Care
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
30 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Not applicable Interventional

iChoose Decision Kidney Aid for End-Stage Renal Disease Patients

NCT02235571
View directory record Official record
Conditions
End-Stage Kidney Disease, Kidney Failure, Chronic, Kidney Transplantation
Interventions
iChoose Kidney Decision Aid
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis

NCT03694444
View directory record Official record
Conditions
Gingivitis
Interventions
AMY-101, Water for injection
Drug · Other
Lead sponsor
Amyndas Pharmaceuticals S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

10-Week Physical Activity Program for Mothers of Children With Developmental Disabilities

NCT07182071
View directory record Official record
Conditions
Caregiver Burden
Interventions
Physical Activity Program, Waitlist for Physical Activity Program
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Truway Whole-Body Digital Twin and Physiologic Resilience Study (TRU-OMNIBODY)

NCT07805044
View directory record Official record
Conditions
PHYSIOLOGICAL PHENOMENA, Homeostasis, Physical Functional Performance, Cardiorespiratory Fitness, Cardiometabolic Risk Factors, Mobility Limitation
Interventions
Standardized Physiologic Resilience Challenge, Multimodal Whole-Body Physiologic Monitoring, Research-Only Whole-Body Digital Twin Analysis
Procedure · Other
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2041
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Impact of Night Float on Anesthesiology Resident Sleep Patterns

NCT03325244
View directory record Official record
Conditions
Sleep Disorders, Circadian Rhythm
Interventions
EEG monitor, FitBit
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

"Eye Protection After Mydriatic Use for ROP Screening: Impact on Vitals Signs and Pain Scores"

NCT01860534
View directory record Official record
Conditions
Light Sensitivity
Interventions
eye covers
Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 22, 2026, 4:50 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Right-sided Retroflexion With Standard Adult Versus Pediatric Colonoscopes

NCT01675934
View directory record Official record
Conditions
Colonic Neoplasms
Interventions
Retroflexion with the adult colonoscope., Retroflexion with the pediatric colonoscope.
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 8, 2016 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Characterize Puff Topography With Use of JUUL 5% Electronic Nicotine Delivery Systems (ENDS) in Adult Smokers

NCT03596034
View directory record Official record
Conditions
Tobacco Use, Nicotine Dependence, Other Tobacco Product, Tobacco Smoking
Interventions
JUUL 5%, Virginia Tobacco, ENDS product
Other
Lead sponsor
Juul Labs, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Charlotte, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 22, 2026, 4:50 AM EDT
Recruiting Phase 2 Interventional

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

NCT05281809
View directory record Official record
Conditions
B-Cell Lymphoma, B Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Chronic Lymphocytic Leukemia, Transformed Lymphoma
Interventions
Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
Drug
Lead sponsor
John Lister
Other
Eligibility
18 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 22, 2026, 4:50 AM EDT
Withdrawn Phase 2 Interventional

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

NCT05293509
View directory record Official record
Conditions
Stem Cell Transplantation
Interventions
Fludarabine, Dexamethasone, Cyclophosphamide, Bortezomib, Rituximab, Busulfan, Cyclophosphamide (Cy), Tacrolimus (or cyclosporine), Mycophenolate mofetil (MMF), Rabbit ATG
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 22, 2026, 4:50 AM EDT
Terminated Not applicable Interventional Results available

Low-Dose Total Lymphoid Irradiation in Treating Patients With Refractory Chronic Graft-versus-Host Disease After Donor Stem Cell Transplant

NCT02109809
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
total nodal irradiation, laboratory biomarker analysis, questionnaire administration
Radiation · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 23, 2018 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Not applicable Interventional

A Dietary Source of Potassium Citrate to Resolve Hypocitraturia and Aciduria in Patients With Kidney Stones

NCT03984409
View directory record Official record
Conditions
Kidney Calculi
Interventions
Kroger low calorie orange juice beverage
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 22, 2026, 4:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer

NCT00526799
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Sorafenib, Topotecan
Drug
Lead sponsor
Daniela Matei, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Galesburg, Illinois • Evansville, Indiana • Fort Wayne, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 22, 2026, 4:50 AM EDT
Recruiting Phase 2 Interventional

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06769698
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
FDC fianlimab+cemiplimab, Cemiplimab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
18
States / cities
Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine

NCT02985398
View directory record Official record
Conditions
Migraine Disorder
Interventions
ALD403 (Eptinezumab)
Biological
Lead sponsor
Alder Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
20
States / cities
San Diego, California • Santa Monica, California • Colorado Springs, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Phase 1 Interventional

Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

NCT00003263
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
recombinant interferon alfa, cisplatin, surgical procedure, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
3
States / cities
Marrero, Louisiana • Philadelphia, Pennsylvania • Newport News, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 22, 2026, 4:50 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study

NCT04754087
View directory record Official record
Conditions
Total Hip Arthroplasty, Degenerative Joint Disease of Hip, Avascular Necrosis of Hip, Rheumatoid Arthritis of Hip, Osteoarthritis, Hip, Osteoarthritis of Hip, Fractures, Hip, Fracture of Hip
Interventions
Vivacit-E and Longevity (HXLPE) Liners
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2033
U.S. locations
6
States / cities
Denver, Colorado • South Bend, Indiana • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Terminated No phase listed Observational

Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration

NCT02339987
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
Saint John's Cancer Institute
Other
Eligibility
15 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM

NCT00597493
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
Sorafenib and Temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 22, 2026, 4:50 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus

NCT07096193
View directory record Official record
Conditions
Chronic Hepatitis Delta
Interventions
GS-4321, GS-4321 Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 69 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
5
States / cities
Anaheim, California • La Jolla, California • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Terminated Early Phase 1 Interventional

Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers

NCT00882193
View directory record Official record
Conditions
Chronic Hepatitis C, Genotype 1, Relapse
Interventions
Betaine, Peginterferon alpha 2a, Ribavirin
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 22, 2026, 4:50 AM EDT